STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at the American Chemical Society Fall 2023 Conference

STORM’s lead programme is the first RNA methyltransferase inhibitor to enter clinical development.

9 August 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting the discovery of its lead clinical candidate, STC-15, which is an orally bioavailable and highly selective METTL3 inhibitor, at the American Chemical Society (ACS) Fall 2023 Conference, in San Francisco, California on the 13-17 August 2023.

Read more…